Two lenders win big in $74bn BMS Celgene merger
The US’s Bristol-Myers Squibb (BMS) has picked two banks to provide the debt portion of its $74bn acquisition of biotech firm Celgene, in one of the biggest pharmaceuticals mergers in recent years.
Morgan Stanley and MUFG have provided fully committed debt financing for the acquisition, announced on Thursday.
The US bank is also lead financial adviser to BMS on the deal, with Evercore and Dyal Co also advisers. JP Morgan and Citigroup are advising Celgene.
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com